Amphastar Beats The Street For Third Consecutive Quarter
Firm Stands To Gain Further In H2 Following Pfizer Tornado Damage
Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.
